Angeion's defibrillator lead to undergo US trials:
This article was originally published in Clinica
Angeion plans to begin a US multicentre clinical trial of its new AngeFix 4090 lead system for defibrillators. The lead helps pace, sense and defibrillate the heart using a helix-shaped active fixation tip which can be "screwed" into the heart tissue and which also reduces the risk of the lead becoming dislodged. The Minneapolis, Minnesota-based company recently CE-marked the device which will be marketed in Europe by ELA Medical, a subsidiary of French company Synthelabo.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.